查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非癌症液态切片活检市场-全球和区域分析：按应用、技术、最终用户和区域-分析和预测（2025-2035年）
市场调查报告书
商品编码
1841465

非癌症液态切片活检市场-全球和区域分析：按应用、技术、最终用户和区域-分析和预测（2025-2035年）

Non-Cancer Liquid Biopsy Testing Market - A Global and Regional Analysis: Focus on Application, Technology, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 146 Pages | 商品交期: 1-5个工作天内

价格

2024 年全球非癌症液态切片切片市场规模为 42.761 亿美元，预计到 2035 年将激增至 193.088 亿美元，2025 年至 2035 年期间的复合年增长率将达到年复合成长率%。

主要市场统计数据
预测期 2025-2035
2025年评估 50.751亿美元
2035年的预测 193.88亿美元
复合年增长率 14.3%

全球非癌症液态切片活检市场的发展受到慢性疾病负担日益加重的驱动，这些疾病涵盖心血管和神经系统疾病、产前和移植护理等，对微创即时诊断的需求也日益增长。透过分析血液中的生物标记物，液态切片能够早期发现并动态监测各种适应症，且无需承担传统采样程序的风险。次世代定序和检测灵敏度的进步，加上业界的巨大投入，使得液态切片成为一种适用于非侵入性产前检测、移植排斥监测和感染疾病检测等应用的方法。然而，由于高昂的资本成本、高昂的单位成本以及不同的报销环境，其广泛应用仍充满挑战。在服务欠缺地区进行工作流程的策略性本地化，例如在国内部署获得CE认证的平台，将为缩短週转时间、降低成本和扩大可及性提供强大的机会，为液态切片成为全球精准医疗和预防医学的基石铺平道路。

市场介绍

随着生物製药和诊断公司将微创、基于血液的分子检测从肿瘤学扩展到产前筛检、移植监测和感染疾病检测等关键领域，全球非癌症液态切片活检市场正在快速成长。液态切片测试，例如 Illumina 的 Verifi、Natera 的 Panorama 和 Karius 的 Spectrum，利用游离 DNA、 微型RNA和外泌体来提供以前需要有风险的组织采样才能获得的早期即时洞察，从而提高患者安全性和操作效率。持续的检测创新和新生物标记的检验，加上战略伙伴关係关係和有针对性的收购，正在本地化先进的工作流程并降低週转时间、成本和物流障碍。随着全球医疗保健系统拥抱精准医疗和预防保健，改进的性能、法规遵从性和数位健康整合的整合使非癌症液态切片成为下一代诊断的关键组成部分。

对产业的影响

非癌症液态切片活检市场正在经历快速的产业化，主要企业利用策略联盟、定向收购和大量资本，将先进的微创工作流程融入当地医疗生态系统。透过与数位医疗服务提供者和本地实验室合作，该公司正在简化端到端诊断路径，缩短週转时间，降低单次检测成本，同时又不损害样本完整性。同时，併购和地理扩张正在增强本土化能力，而产品组合的增强和新产品的发布则拓宽了其应用范围，从产前和移植监测到感染疾病检测。大量的资本流入加速了研发和商业化进程，实现了检测的标准化和大规模合规性。这些产业动态的结合，正在将非癌症液态切片从利基创新转变为一个强大的、全球可及的精准医疗和预防性医疗保健平台。

市场区隔

细分 1：按应用

  • 产前检查
  • 器官移植
  • 其他的

产前检测领域将主导非癌症液态切片检测市场（按应用）

在全球非癌症液态切片活检市场（按应用划分）中，预计到2024年，产前检测将占据79.70%的市场份额，并在预测期内保持主导地位。这反映了产前检测的微创特性、无风险的单次采血通讯协定、广泛的报销范围以及通用的指南支援。这些因素共同支持了非癌症液态切片领域产前检测的成长。

细分领域二：技术

  • NGS
  • PCR
  • 其他的

NGS 主导非癌症液态切片检测市场（按技术）

在全球非癌症液态切片检测市场（按技术划分）中，NGS 在 2024 年占据了 59.68% 的市场份额，并且由于其无与伦比的能力，可以在单次检测中实现全面、高通量基因组分析，并且由于技术进步和规模效率的提高，每个样本的成本稳步下降，预计在预测期内仍将保持主导地位。

细分 3：按最终用户

  • 临床
  • 研究

非癌症液态切片检测市场的临床主导地位（按最终用户）

在全球非癌症液态切片检测市场（按最终用户划分）中，预计临床应用领域将在2024年占据86.22%的市场份额，并有望在预测期内保持主导地位，这得益于液态切片在临床实验室的快速应用，以及製药和生物技术公司在药物开发和临床试验监测中的应用日益增多。这种主导地位反映了强大的报销途径、与常规患者照护的融合，以及临床实践和治疗创新对微创诊断日益增长的需求。

细分4：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • UAE
    • 南非
    • 南非
    • 其他的

预计预测期内亚太非癌症液态切片检测市场将以 15.77% 的显着速度成长。

近期动态

  • 2025 年 5 月，BillionToOne, Inc. 推出了扩展的 UNITY 胎儿风险筛检，该筛检最早可在怀孕九週时透过单一血液样本评估胎儿多达 14 种遗传疾病的风险。
  • 该服务利用 IONA Nx NIPT 工作流程对包括微缺失在内的遗传疾病进行准确筛检。
  • 2025 年 2 月，Acrannolife Genomics 与 GOQii 合作启动了一项旨在透过先进的数位和基因组解决方案加强印度移植后护理的计划。

需求——驱动因素、挑战、机会

市场驱动因素：

疾病负担日益加重，筛检日益增长——由于慢性病负担日益加重以及对非侵入性诊断工具的需求不断增长，全球非癌症液态切片活检市场正在蓬勃发展。液态切片透过分析cfDNA和循环/外泌体miRNA等生物标记物，能够早期发现和监测心血管和神经系统疾病等疾病。液态切片能够即时洞察传统组织切片检查难以获得的疾病讯息，并应用于其他领域。它们不仅支持心臟和大脑健康，还支持器官移植、产前检测和感染疾病管理等应用。

市场挑战：

不确定的报销状况和高昂的设置成本阻碍了其广泛应用——非肿瘤科液态切片检测的普及受到报销状况不明确和不一致的限制，尤其是在肿瘤科以外的领域。儘管液体活检具有临床潜力，但付款方要求更有力的成本效益证据，而且技术的快速进步往往超过政策更新的速度。先进定序平台的高昂设定成本和每次检测的高昂价格进一步限制了其普及，尤其是在缺乏保险覆盖的情况下。这些挑战阻碍了液体活检在临床上的广泛应用，尤其是在产前诊断、感染疾病和移植相关诊断方面。

市场机会：

扩大服务欠缺地区的可及性——非肿瘤液态切片公司正在服务欠缺地区本地化先进的诊断服务，以改善可及性并减少对海外实验室的依赖。实施内部工作流程，例如 Yourgene Health 在摩洛哥和哥伦比亚的 NIPT 解决方案，可以缩短週转时间、降低成本并减少检测失败率。此类努力能够更快、更准确地进行诊断，同时增强临床自主性。这种方法为产前、移植和感染疾病诊断领域的广泛应用提供了可扩展的机会，从而促进了健康公平和市场渗透。

产品/创新策略：全球非癌症液态切片检测市场已根据应用、技术、最终用户、地区等不同类别进行广泛细分。这有助于读者清楚了解哪个细分市场占有最大份额以及哪个细分市场在未来几年可能会成长。

伙伴关係关係占重大发展的最大数量，占2022年1月至2025年5月期间全球非癌症液态切片检测市场总发展的近40％。

全球非癌症液态切片检测市场拥有众多现有企业及其产品系列。本研究分析并概述了全球非癌症液态切片检测市场中的主要企业概况，包括提供非癌症液态切片检测系统产品的现有企业。

主要市场参与企业和竞争概况

公司简介是根据对公司范围、产品系列和市场渗透率的分析所收集的资讯而选择的。

该市场的一些知名参与者包括：

  • AcrannoLife Genomics
  • Agilent Technologies, Inc.
  • BillionToOne Inc.
  • BGI Group
  • CareDx Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Karius, Inc.
  • Laboratory Corporation of America Holdings
  • Lilac Insights Pvt. Ltd.
  • MedGenome Labs Ltd.
  • Natera, Inc.
  • Yourgene Health (Novacyt Group)
  • Oncocyte Corporation

目录

执行摘要

第一章市场：产业展望

  • 市场动态
  • 趋势
  • 市场动态
  • 监管状况/合规性
  • 赎回情景
  • 采用和使用趋势
  • 专利分析

第二章 应用

  • 使用摘要
  • 非癌症液态切片检测市场（按应用）
    • 产前检查
    • 器官移植
    • 其他的

第三章 技术

  • 技术摘要
  • 非癌症液态切片检测市场（按技术）
    • NGS
    • PCR
    • 其他的

第四章 最终用户

  • 最终用户摘要
  • 非癌症液态切片检测市场（按最终用户划分）
    • 研究
    • 临床

第五章 试验次数

  • 试验次数摘要
  • 非癌症液态切片检测数量（按应用）
    • 产前检查
    • 器官移植
    • 其他的

第六章 区域

  • 区域摘要
  • 北美洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 测试次数
    • 按最终用户
    • 按国家
    • 美国
    • 加拿大
  • 欧洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 测试次数
    • 按最终用户
    • 按国家
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 测试次数
    • 按最终用户
    • 按国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 测试次数
    • 按最终用户
    • 按国家
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 测试次数
    • 按最终用户
    • 按国家
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他的

7. 市场 - 竞争基准化分析与公司简介

  • 竞争基准化分析
  • 未满足的需求
  • 液态切片的新应用
  • 产品基准
  • 公司简介
    • AcrannoLife Genomics
    • Agilent Technologies, Inc.
    • BillionToOne Inc.
    • BGI Group
    • CareDx Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
    • Illumina, Inc.
    • Karius, Inc.
    • Laboratory Corporation of America Holdings
    • Lilac Insights Pvt. Ltd.
    • MedGenome Labs Ltd.
    • Natera, Inc.
    • Yourgene Health (Novacyt Group)
    • Oncocyte Corporation

第八章调查方法

This report can be delivered within 1 working day.

Introduction of Non-Cancer Liquid Biopsy Testing Market

The global non-cancer liquid biopsy testing market, initially valued at $4,276.1 million in 2024, is projected to witness substantial growth, surging to $19,308.8 million by 2035, marking a remarkable compound annual growth rate (CAGR) of 14.30% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$5,075.1 Million
2035 Forecast$19,308.8 Million
CAGR14.3%

The global non-cancer liquid biopsy testing market is being propelled by the rising burden of chronic diseases, from cardiovascular and neurological disorders to prenatal and transplant care, and the growing demand for minimally invasive, real-time diagnostics. By analyzing blood-based biomarkers, liquid biopsy enables early detection and dynamic monitoring across a spectrum of indications without the risks of traditional sampling procedures. Advances in next-generation sequencing and assay sensitivity, coupled with significant industry investment, have positioned liquid biopsy as the preferred approach for applications such as non-invasive prenatal testing, graft-rejection surveillance and infectious-disease detection. However, high capital and per-test costs, along with an uneven reimbursement environment, continue to challenge widespread adoption. Strategic localization of workflows in underserved regions, exemplified by in-country deployments of CE-marked platforms, offers a powerful opportunity to reduce turnaround times, lower costs and broaden access, paving the way for liquid biopsy to become a cornerstone of precision and preventive medicine worldwide.

Market Introduction

The global non-cancer liquid biopsy testing market is rapidly growing as biopharma and diagnostics companies extend minimally invasive, blood-based molecular assays beyond oncology into critical areas such as prenatal screening, transplant surveillance and infectious-disease detection. By leveraging cell-free DNA, microRNAs and exosomes, liquid biopsy tests such as Illumina's Verifi, Natera's Panorama and Karius' Spectrum, deliver early, real-time insights that traditionally required risky tissue sampling, improving patient safety and operational efficiency. Ongoing assay innovations and novel biomarker validations, combined with strategic partnerships, and targeted acquisitions, are localizing advanced workflows and reducing turnaround times, costs and logistical hurdles. As healthcare systems worldwide embrace precision and preventive medicine, the convergence of enhanced performance, regulatory compliance and digital-health integration positions non-cancer liquid biopsy as a cornerstone of next-generation diagnostics.

Industrial Impact

The non-cancer liquid biopsy testing market is witnessing rapid industrialization as key players leverage strategic alliances, targeted acquisitions, and significant funding to embed advanced, minimally invasive workflows within regional healthcare ecosystems. By partnering with digital-health providers and local laboratories, companies are streamlining end-to-end diagnostic pathways, slashing turnaround times and reducing per-test costs without compromising sample integrity. Simultaneously, mergers and geographic expansions are strengthening in-country capacities, while portfolio enhancements and new product launches are broadening application scopes, from prenatal and transplant monitoring to infectious-disease detection. Substantial capital inflows have accelerated R&D and commercialization, enabling assay standardization and regulatory compliance at scale. Together, these industrial dynamics are transforming non-cancer liquid biopsy from a niche innovation into a robust, globally accessible platform for precision and preventive medicine.

Market Segmentation:

Segmentation 1: by Application

  • Prenatal Testing
  • Organ Transplantation
  • Others

Prenatal Testing Segment to Dominate the Non-Cancer Liquid Biopsy Testing Market (by Application)

The global non-cancer liquid biopsy testing market (by application) has been dominated by prenatal testing, representing 79.70% of the market share in 2024, and is expected to maintain its dominance during the forecast period. This reflects prenatal testing's minimally invasive, single-blood-draw protocol with no risk, broad reimbursement coverage and universal guideline endorsements. These factors collectively support the growth of the prenatal testing in the non-cancer liquid biopsy space

Segmentation 2: Technology

  • NGS
  • PCR
  • Others

NGS to Dominate the Non-Cancer Liquid Biopsy Testing Market (by Technology)

The global non-cancer liquid biopsy testing market (by technology) has been dominated by NGS, representing 59.68% of the market share in 2024, and is expected to maintain its dominance during the forecast period due to its unparalleled capacity for comprehensive, high-throughput genomic profiling in a single assay and its steadily declining per-sample costs enabled by technological advances and scale efficiencies.

Segmentation 3: by End User

  • Clinical
  • Research

Clinical to Dominate the Non-Cancer Liquid Biopsy Testing Market (by End User)

The global non-cancer liquid biopsy testing market (by end user) has been dominated by clinical segment, representing 86.22% of the market share in 2024, and is expected to maintain its dominance during the forecast period driven by rapid adoption of liquid biopsy in clinical laboratories and increasing utilization by pharmaceutical and biotech companies for drug development and clinical trial monitoring. This dominance reflects strong reimbursement pathways, integration into routine patient care and the escalating demand for minimally invasive diagnostics in both clinical practice and therapeutic innovation.

Segmentation 4: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • U.A.E.
    • K.S.A.
    • South Africa
    • Rest-of-Middle East and Africa

The non-cancer liquid biopsy testing market in the Asia-Pacific region is expected to witness a significant growth rate of 15.77% during the forecast period.

Recent Developments

  • In May 2025, BillionToOne, Inc. launched an expanded UNITY Fetal Risk Screen to assess fetal risk for up to 14 genetic conditions from a single blood sample as early as nine weeks into pregnancy.
  • In Febrauary 2025, Yourgene Health launched IONA Care+, a comprehensive non-invasive prenatal testing (NIPT) service in the U.K. This service utilizes the IONA Nx NIPT Workflow to provide accurate screening for genetic conditions, including microdeletions.
  • In Febrauary 2025, Acrannolife Genomics partnered with GOQii to launch a program aimed at enhancing post-transplant care in India through advanced digital and genomic solutions.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Growing Disease Burden and Screening: The global non-cancer liquid biopsy testing market is witnessing growth due to the rising burden of chronic diseases and the need for non-invasive diagnostic tools. Liquid biopsy enables early detection and monitoring of conditions like cardiovascular and neurological disorders by analyzing biomarkers such as cfDNA and circulating/exosomal miRNAs. It offers real-time disease insights, particularly where traditional tissue biopsies are difficult. Beyond heart and brain health, it also supports applications in organ transplantation, prenatal testing, and infectious disease management.

Market Challenges:

Uncertain Reimbursement Landscape and High Setup Costs Hindering Widespread Adoption: The adoption of non-cancer liquid biopsy tests is limited by an uncertain and inconsistent reimbursement landscape, especially outside oncology applications. Despite their clinical potential, payers demand stronger evidence of cost-effectiveness, and rapid technological advancements often outpace policy updates. High setup costs for advanced sequencing platforms and expensive per-test pricing further restrict access, especially without insurance coverage. These challenges hinder widespread clinical integration, particularly in prenatal, infectious disease, and transplant-related diagnostics.

Market Opportunities:

Expanding Access in Underserved Regions: Non-cancer liquid biopsy companies are localizing advanced diagnostic services in underserved regions to improve access and reduce reliance on overseas labs. By implementing in-house workflows, such as Yourgene Health's NIPT solutions in Morocco and Colombia, they've reduced turnaround times, costs, and test failures. These efforts enable faster, more accurate diagnoses while enhancing clinical autonomy. This approach presents a scalable opportunity for wider adoption across prenatal, transplant, and infectious disease diagnostics, promoting health equity and deeper market penetration.

How can this report add value to an organization?

Product/Innovation Strategy: The global non-cancer liquid biopsy testing market has been extensively segmented based on various categories, such as application, technology, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships accounted for the maximum number of key developments, i.e., nearly 40% of the total developments in the global non-cancer liquid biopsy testing market were between January 2022 and May 2025.

Competitive Strategy: The global non-cancer liquid biopsy testing market has numerous established players with product portfolios. Key players in the global non-cancer liquid biopsy testing market analyzed and profiled in the study include established players offering products for non-cancer liquid biopsy testing systems.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2022-FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world.
  • The market contribution of non-cancer liquid biopsy testing is anticipated to be launched in the future and has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available non-cancer liquid biopsy tests. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in non-cancer liquid biopsy testing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • AcrannoLife Genomics
  • Agilent Technologies, Inc.
  • BillionToOne Inc.
  • BGI Group
  • CareDx Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Karius, Inc.
  • Laboratory Corporation of America Holdings
  • Lilac Insights Pvt. Ltd.
  • MedGenome Labs Ltd.
  • Natera, Inc.
  • Yourgene Health (Novacyt Group)
  • Oncocyte Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Market Dynamics
    • 1.1.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
  • 1.2 Trends
    • 1.2.1 Expansion of Liquid Biopsy in Non-Cancerous Applications
    • 1.2.2 Increasing Strategic Initiatives to Increase the Uptake of Liquid Biopsy for Non-Oncology Applications
  • 1.3 Market Dynamics
    • 1.3.1 Market Drivers
      • 1.3.1.1 Growing Disease Burden and Screening
      • 1.3.1.2 Growing Adoption and Demand for Non-Invasive Diagnostics
    • 1.3.2 Market Challenges
      • 1.3.2.1 Uncertain Reimbursement Landscape and High Setup Costs Hindering Widespread Adoption
    • 1.3.3 Business Strategies
      • 1.3.3.1 Product Launch/Expansion
    • 1.3.4 Corporate Strategies
      • 1.3.4.1 Partnerships
      • 1.3.4.2 Funding Activities
      • 1.3.4.3 Merger and Acquisitions
    • 1.3.5 Market Opportunities
      • 1.3.5.1 Expanding Access in Underserved Regions
  • 1.4 Regulatory Landscape/Compliance
    • 1.4.1 U.S.
    • 1.4.2 Europe
  • 1.5 Reimbursement Scenario
    • 1.5.1 U.S.
    • 1.5.2 Europe
    • 1.5.3 Asia-Pacific
  • 1.6 Adoption and Utilization Trends
    • 1.6.1 Regional Adoption Disparities
    • 1.6.2 Shift to Decentralized Testing
    • 1.6.3 Technology Migration
  • 1.7 Patent Analysis
    • 1.7.1 Patent Analysis (by Year)
    • 1.7.2 Patent Analysis (by Country)

2 Application

  • 2.1 Application Summary
  • 2.2 Non-Cancer Liquid Biopsy Testing Market (by Application)
    • 2.2.1 Prenatal Testing
    • 2.2.2 Organ Transplantation
      • 2.2.2.1 Kidney
      • 2.2.2.2 Lung
      • 2.2.2.3 Others
    • 2.2.3 Other Applications

3 Technology

  • 3.1 Technology Summary
  • 3.2 Non-Cancer Liquid Biopsy Testing Market (by Technology)
    • 3.2.1 NGS
    • 3.2.2 PCR
    • 3.2.3 Others

4 End User

  • 4.1 End User Summary
  • 4.2 Non-Cancer Liquid Biopsy Testing Market (by End User)
    • 4.2.1 Research
    • 4.2.2 Clinical
      • 4.2.2.1 Clinical Laboratories
      • 4.2.2.2 Pharmaceutical and Biotechnology Companies
      • 4.2.2.3 Others

5 Test Volume

  • 5.1 Test Volume Summary
  • 5.2 Non-Cancer Liquid Biopsy Testing Volume (by Application)
    • 5.2.1 Prenatal Testing
    • 5.2.2 Organ Transplantation
    • 5.2.3 Others

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Test Volume
    • 6.2.5 By End User
    • 6.2.6 By Country
    • 6.2.7 U.S.
      • 6.2.7.1 Test Volume
      • 6.2.7.2 By End User
    • 6.2.8 Canada
      • 6.2.8.1 Test Volume
      • 6.2.8.2 By End User
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Test Volume
    • 6.3.5 By End User
    • 6.3.6 By Country
    • 6.3.7 U.K.
      • 6.3.7.1 Test Volume
      • 6.3.7.2 By End User
    • 6.3.8 Germany
      • 6.3.8.1 Test Volume
      • 6.3.8.2 By End User
    • 6.3.9 France
      • 6.3.9.1 Test Volume
      • 6.3.9.2 By End User
    • 6.3.10 Italy
      • 6.3.10.1 Test Volume
      • 6.3.10.2 By End User
    • 6.3.11 Spain
      • 6.3.11.1 Test Volume
      • 6.3.11.2 By End User
    • 6.3.12 Rest-of-Europe
      • 6.3.12.1 Test Volume
      • 6.3.12.2 By End User
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Test Volume
    • 6.4.5 By End User
    • 6.4.6 By Country
    • 6.4.7 Japan
      • 6.4.7.1 Test Volume
      • 6.4.7.2 By End User
    • 6.4.8 China
      • 6.4.8.1 Test Volume
      • 6.4.8.2 By End User
    • 6.4.9 India
      • 6.4.9.1 Test Volume
      • 6.4.9.2 By End User
    • 6.4.10 Australia
      • 6.4.10.1 Test Volume
      • 6.4.10.2 By End User
    • 6.4.11 Rest-of-the-Asia-Pacific
      • 6.4.11.1 Test Volume
      • 6.4.11.2 By End User
  • 6.5 Latin America
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Test Volume
    • 6.5.5 By End User
    • 6.5.6 By Country
    • 6.5.7 Brazil
      • 6.5.7.1 Test Volume
      • 6.5.7.2 By End User
    • 6.5.8 Mexico
      • 6.5.8.1 Test Volume
      • 6.5.8.2 By End User
    • 6.5.9 Rest-of-Latin America
      • 6.5.9.1 Test Volume
      • 6.5.9.2 By End User
  • 6.6 Middle East and Africa
    • 6.6.1 Regional Overview
    • 6.6.2 Driving Factors for Market Growth
    • 6.6.3 Factors Challenging the Market
    • 6.6.4 Test Volume
    • 6.6.5 By End User
    • 6.6.6 By Country
    • 6.6.7 U.A.E.
      • 6.6.7.1 Test Volume
      • 6.6.7.2 By End User
    • 6.6.8 K.S.A.
      • 6.6.8.1 Test Volume
      • 6.6.8.2 By End User
    • 6.6.9 South Africa
      • 6.6.9.1 Test Volume
      • 6.6.9.2 By End User
    • 6.6.10 Rest-of-Middle East and Africa
      • 6.6.10.1 Test Volume
      • 6.6.10.2 By End User

7 Markets - Competitive Benchmarking & Company Profiles

  • 7.1 Competitive Benchmarking
    • 7.1.1 Growth-Share Matrix
      • 7.1.1.1 By Application
      • 7.1.1.2 By Technology
      • 7.1.1.3 By End User
  • 7.2 Unmet Needs
  • 7.3 Emerging Applications of Liquid Biopsy
    • 7.3.1 Infectious Disease Diagnosis and Management
    • 7.3.2 Neurological Disorders
    • 7.3.3 Autoimmune and Inflammatory Diseases
    • 7.3.4 Cardiovascular Disease Monitoring
  • 7.4 Product Benchmarking
  • 7.5 Company Profiles
    • 7.5.1 AcrannoLife Genomics
      • 7.5.1.1 Overview
      • 7.5.1.2 Top Products/Product Portfolio
      • 7.5.1.3 Top Competitors
      • 7.5.1.4 Target Customers
      • 7.5.1.5 Key Personal
      • 7.5.1.6 Analyst View
    • 7.5.2 Agilent Technologies, Inc.
      • 7.5.2.1 Overview
      • 7.5.2.2 Top Products/Product Portfolio
      • 7.5.2.3 Top Competitors
      • 7.5.2.4 Target Customers
      • 7.5.2.5 Key Personal
      • 7.5.2.6 Analyst View
    • 7.5.3 BillionToOne Inc.
      • 7.5.3.1 Overview
      • 7.5.3.2 Top Products/Product Portfolio
      • 7.5.3.3 Top Competitors
      • 7.5.3.4 Target Customers
      • 7.5.3.5 Key Personal
      • 7.5.3.6 Analyst View
    • 7.5.4 BGI Group
      • 7.5.4.1 Overview
      • 7.5.4.2 Top Products/Product Portfolio
      • 7.5.4.3 Top Competitors
      • 7.5.4.4 Target Customers
      • 7.5.4.5 Key Personal
      • 7.5.4.6 Analyst View
    • 7.5.5 CareDx Inc.
      • 7.5.5.1 Overview
      • 7.5.5.2 Top Products/Product Portfolio
      • 7.5.5.3 Top Competitors
      • 7.5.5.4 Target Customers
      • 7.5.5.5 Key Personal
      • 7.5.5.6 Analyst View
      • 7.5.5.7 Market Share, 2023
    • 7.5.6 Eurofins Scientific SE
      • 7.5.6.1 Overview
      • 7.5.6.2 Top Products/Product Portfolio
      • 7.5.6.3 Top Competitors
      • 7.5.6.4 Target Customers
      • 7.5.6.5 Key Personal
      • 7.5.6.6 Analyst View
      • 7.5.6.7 Market Share, 2023
    • 7.5.7 F. Hoffmann-La Roche Ltd.
      • 7.5.7.1 Overview
      • 7.5.7.2 Top Products/Product Portfolio
      • 7.5.7.3 Top Competitors
      • 7.5.7.4 Target Customers
      • 7.5.7.5 Key Personal
      • 7.5.7.6 Analyst View
    • 7.5.8 Illumina, Inc.
      • 7.5.8.1 Overview
      • 7.5.8.2 Top Products/Product Portfolio
      • 7.5.8.3 Top Competitors
      • 7.5.8.4 Target Customers
      • 7.5.8.5 Key Personal
      • 7.5.8.6 Analyst View
    • 7.5.9 Karius, Inc.
      • 7.5.9.1 Overview
      • 7.5.9.2 Top Products/Product Portfolio
      • 7.5.9.3 Top Competitors
      • 7.5.9.4 Target Customers
      • 7.5.9.5 Key Personal
      • 7.5.9.6 Analyst View
    • 7.5.10 Laboratory Corporation of America Holdings
      • 7.5.10.1 Overview
      • 7.5.10.2 Top Products/Product Portfolio
      • 7.5.10.3 Top Competitors
      • 7.5.10.4 Target Customers
      • 7.5.10.5 Key Personal
      • 7.5.10.6 Analyst View
    • 7.5.11 Lilac Insights Pvt. Ltd.
      • 7.5.11.1 Overview
      • 7.5.11.2 Top Products/Product Portfolio
      • 7.5.11.3 Top Competitors
      • 7.5.11.4 Target Customers
      • 7.5.11.5 Key Personal
      • 7.5.11.6 Analyst View
    • 7.5.12 MedGenome Labs Ltd.
      • 7.5.12.1 Overview
      • 7.5.12.2 Top Products/Product Portfolio
      • 7.5.12.3 Top Competitors
      • 7.5.12.4 Target Customers
      • 7.5.12.5 Key Personal
      • 7.5.12.6 Analyst View
    • 7.5.13 Natera, Inc.
      • 7.5.13.1 Overview
      • 7.5.13.2 Top Products/Product Portfolio
      • 7.5.13.3 Top Competitors
      • 7.5.13.4 Target Customers
      • 7.5.13.5 Key Personal
      • 7.5.13.6 Analyst View
    • 7.5.14 Yourgene Health (Novacyt Group)
      • 7.5.14.1 Overview
      • 7.5.14.2 Top Products/Product Portfolio
      • 7.5.14.3 Top Competitors
      • 7.5.14.4 Target Customers
      • 7.5.14.5 Key Personal
      • 7.5.14.6 Analyst View
    • 7.5.15 Oncocyte Corporation
      • 7.5.15.1 Overview
      • 7.5.15.2 Top Products/Product Portfolio
      • 7.5.15.3 Top Competitors
      • 7.5.15.4 Target Customers
      • 7.5.15.5 Key Personal
      • 7.5.15.6 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Non-Cancer Liquid Biopsy Testing Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Global Market Snapshot, 2024
  • Figure 3: Global Non-Cancer Liquid Biopsy Testing Market, $Million, 2024 and 2035
  • Figure 4: Non-Cancer Liquid Biopsy Testing Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 5: Non-Cancer Liquid Biopsy Testing Market (by Technology), $Million, 2024, 2030, and 2035
  • Figure 6: Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 7: Global Non-Cancer Liquid Biopsy Testing Market Segmentation
  • Figure 8: Global Non-Cancer Liquid Biopsy Testing Market, Patent Analysis (by Year), January 2020-December 2024
  • Figure 9: Global Non-Cancer Liquid Biopsy Testing Market, Patent Analysis (by Country), January 2021- December 2024
  • Figure 10: Global Non-Cancer Liquid Biopsy Testing Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 11: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Prenatal Testing), $Million, 2024-2035
  • Figure 12: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Infectious Diseases), $Million, 2024-2035
  • Figure 13: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Organ Transplantation), $Million, 2024-2035
  • Figure 14: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Organ Transplantation), $Million, 2024-2035
  • Figure 15: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Organ Transplantation), $Million, 2024-2035
  • Figure 16: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Organ Transplantation), $Million, 2024-2035
  • Figure 17: Global Non-Cancer Liquid Biopsy Testing Market (by Application, Other Applications), $Million, 2024-2035
  • Figure 18: Global Non-Cancer Liquid Biopsy Testing Market (by Technology), $Million, 2024, 2030, and 2035
  • Figure 19: Global Non-Cancer Liquid Biopsy Testing Market (by Technology, NGS), $Million, 2024-2035
  • Figure 20: Global Non-Cancer Liquid Biopsy Testing Market (by Technology, PCR), $Million, 2024-2035
  • Figure 21: Global Non-Cancer Liquid Biopsy Testing Market (by Technology, Others), $Million, 2024-2035
  • Figure 22: Global Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 23: Global Non-Cancer Liquid Biopsy Testing Market (by End User, Research), $Million, 2024-2035
  • Figure 24: Global Non-Cancer Liquid Biopsy Testing Market (by End User, Clinical), $Million, 2024-2035
  • Figure 25: Global Non-Cancer Liquid Biopsy Testing Market (by Clinical, Clinical Laboratories), $Million, 2024-2035
  • Figure 26: Global Non-Cancer Liquid Biopsy Testing Market (by Clinical, Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
  • Figure 27: Global Non-Cancer Liquid Biopsy Testing Market (by Clinical, Others), $Million, 2024-2035
  • Figure 28: Global Non-Cancer Liquid Biopsy Testing Volume (by Application), Thousand, 2024, 2030, and 2035
  • Figure 29: Global Non-Cancer Liquid Biopsy Testing Volume (by Application), Thousand, 2024-2035
  • Figure 30: Global Non-Cancer Liquid Biopsy Testing Volume (by Application), Thousand, 2024-2035
  • Figure 31: Global Non-Cancer Liquid Biopsy Testing Volume (by Application), Thousand, 2024-2035
  • Figure 32: North America Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 33: U.S. Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 34: U.S. Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 35: Canada Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 36: Canada Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 37: Europe Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 38: U.K. Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 39: U.K. Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 40: Germany Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 41: Germany Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 42: France Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 43: France Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 44: Italy Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 45: Italy Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 46: Spain Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 47: Spain Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 48: Rest-of-Europe Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 49: Rest-of-Europe Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 50: Asia-Pacific Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 51: Japan Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 52: Japan Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 53: China Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 54: China Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 55: India Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 56: India Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 57: Australia Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 58: Australia Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 59: Rest-of-Asia-Pacific Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 60: Rest-of-the-Asia-Pacific Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 61: Latin America Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 62: Brazil Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 63: Brazil Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 64: Mexico Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 65: Mexico Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 66: Rest-of-Latin America Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 67: Rest-of-Latin America Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 68: Middle East and Africa Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 69: U.A.E. Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 70: U.A.E. Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 71: K.S.A. Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 72: K.S.A. Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 73: South Africa Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 74: South Africa Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 75: Rest-of-Middle East and Africa Non-Cancer Liquid Biopsy Testing Market, $Million, 2024-2035
  • Figure 76: Rest-of-Middle East and Africa Non-Cancer Liquid Biopsy Testing Market, Test Volume, Thousand, 2024-2035
  • Figure 77: Growth-Share Analysis for Global Non-Cancer Liquid Biopsy Testing Market (by Application), 2024-2035
  • Figure 78: Growth-Share Analysis for Global Non-Cancer Liquid Biopsy Testing Market (by Technology), 2024-2035
  • Figure 79: Growth-Share Analysis for Global Non-Cancer Liquid Biopsy Testing Market (by End User), 2024-2035
  • Figure 80: Global Non-Cancer Liquid Biopsy Testing Market, Unmet Needs
  • Figure 81: Global Non-Cancer Liquid Biopsy Testing Market, Product Benchmarking (by Application)
  • Figure 82: Data Triangulation
  • Figure 83: Top-Down and Bottom-Up Approach
  • Figure 84: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Recent Strategic Activities in Non-Cancer Liquid Biopsy Testing Market
  • Table 3: Reimbursement Rate for Non-Cancer Liquid Biopsy Testing, U.S.
  • Table 4: Global Non-Cancer Liquid Biopsy Testing Market (by Region), $Million, 2024-2035
  • Table 5: Global Non-Cancer Liquid Biopsy Testing Volume (by Region), Thousand, 2024-2035
  • Table 6: North America Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 7: U.S. Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 8: Canada Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 9: Europe Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 10: U.K. Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 11: Germany Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 12: France Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 13: Italy Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 14: Spain Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 15: Rest-of-Europe Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 16: Asia-Pacific Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 17: Japan Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 18: China Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 19: India Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 20: Australia Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 21: Rest-of-the-Asia-Pacific Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 22: Latin America Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 23: Brazil Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 24: Mexico Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 25: Rest-of-Latin America Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 26: Middle East and Africa Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 27: U.A.E. Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 28: K.S.A. Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 29: South Africa Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035
  • Table 30: Rest-of-Middle East and Africa Non-Cancer Liquid Biopsy Testing Market (by End User), $Million, 2024-2035